Patent · US Active

Recombinant constructs of Borrelia burgdorferi

US7605248B2 · kind B2 · utility

0Cited by
13References
12Claims
0Family size

Assignees

Inventors

Key dates

Filing dateSep 26, 2006
Grant dateOct 20, 2009
Priority date
Expiry dateOct 18, 2026

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY02A50/30
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for immunodiagnostic reagents.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.